I kontrollerede, kliniske undersøgelser af patienter med hypertension var den samlede forekomst af bivirkninger sammenlignelig med placebos og overensstemmende med valsartans farmakologi.
In controlled clinical studies in patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan.